"There is an urgent need for highly effective and affordable Cholera vaccines both for outbreaks as well as mass vaccination campaigns."
New Delhi, June 17 - Two global pharmaceutical firms - Hilleman Laboratories and Gotovax AB - Tuesday joined hands to develop affordable oral cholera vaccine.

Our partnership with Gotovax AB is carefully aligned to Hilleman Laboratories' core philosophy of addressing unmet health needs of the underprivileged by developing accessible and innovative vaccines which are affordable, Hilleman Laboratories' chief executive officer Davinder Gill said.

Hilleman Laboratories is a Merck & Co and UK-based Wellcome Trust joint venture while Gotovax AB is a bio-pharmaceutical firm.

There is an urgent need for highly effective and affordable Cholera vaccines both for outbreaks as well as mass vaccination campaigns.

Cholera is endemic in over 50 countries with estimated mortality of 100,000-120,000 deaths each year and a morbidity of 3.8-4.4 million annual cases attributed to this disease, he added.


comments powered by Disqus
Read more on:
 

PERMALINK

http://www.nerve.in/news:2535002381960
You can quote the permanent link above for a direct link to the story. We do not archive or expire our news stories.


STORY OPTIONS
  Email this story to a friend
  XML feed for India


 
COPYRIGHTS INFORMATION
All rights reserved for news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.
Contact Nerve Staff for any feedback, corrections and omissions in news stories.
 

All rights reserved for the news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.